The approval is based on the results from the CheckMate-9DW trial, in which 85% of patients in the comparator arm were treated with lenvatinib and 15% were treated with sorafenib monotherapy.

"Targeting lipid metabolism with Aramchol, a potent SCD1 inhibitor, is a promising emerging strategy to overcome TKIs, such as Sorafenib, Regorafenib or Lenvatinib, for therapy resistance in HCC ...

4 The aim of the study was to test nivolumab/ipilimumab compared with either sorafenib or lenvatinib, which are standards of care for HCC. There were 668 patients who were enrolled in the study ...

Those in the control arm received either 8 or 12 mg lenvatinib daily or 400 mg sorafenib twice daily until disease progression or unacceptable toxicity, according to early results from the trial ...

FDA Approves Combo of Opdivo Plus Yervoy for Advanced Liver Cancer By Lori Solomon HealthDay Reporter TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved ...

At 3 years, Opdivo plus Yervoy led to an overall survival rate of 38% in patients with unresectable or metastatic hepatocellular carcinoma, compared to 24% with lenvatinib or sorafenib monotherapy.